Advertisement

JAK2 Inhibitors for Myeloproliferative Neoplasms: What Is Next?

Although JAK2 inhibitors provide substantial clinical benefit, their disease-modifying activity is limited, and rational combinations with other targeted agents are under study, particularly in myelofibrosis and essential thrombocythemia.

 Blood

click me